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Abstract
Background: Addison’s disease is a potentially life-threatening disorder, and prompt diagnosis, and introduction of steroid
replacement has resulted in near normal life-expectancy. There are limited data describing the clinical presentation of
Addison’s disease in South Africa. It is hypothesised that patients may present in advanced state of ill-health, compared to
Western countries.
Patients: A national database of patients was compiled from primary care, referral centres and private practices. 148
patients were enrolled (97 white, 34 mixed ancestry, 5 Asian and 12 black).
Methods: Demographic and clinical data were elicited using questionnaires. Biochemical data were obtained from folder
reviews and laboratory archived results.
Results: The majority of the cohort was women (62%). The median and inter-quartile age range (IQR) of patients at
enrolment was 46.0 (32.0–61.0) years, with a wide range from 2.8–88.0 years. The median and IQR age at initial diagnosis
was 34.0 (20.0–45.0) years (range 0.02–77.0) years, indicating that at the time of enrolment, the patients, on average, were
diagnosed with Addison’s disease 12 years previously. Hyperpigmentation was observed in 76%, nausea and vomiting
occurred in more than 40%, and weight loss was noted in 25%. Loss of consciousness as a presenting feature was recorded
in 20%. with a 95% confidence interval [CI] of (14–28%) and shock occurred in 5% CI (1.5–8.5%). Case-finding was recorded
at 3.1 per million.
Conclusions: The usual constellation of hyperpigmentation, nausea, vomiting and weight loss suggests Addison’s disease,
but a significant proportion present with an advanced state of ill-health and Addisonian crises. A lower prevalence rate,
compared to Western countries is suggested.
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Introduction
South Africa has a population of 48 million people. In the
absence of national insurance there is an unequal access to health-
care, which consists of a vast public health sector and a small, but
expanding private health sector [1]. Addison’s disease (primary
adrenal insufficiency) results from the destruction of the adrenal
cortex, leading to decreased cortisol and aldosterone production.
These hormones are vital for survival during stressful situations
including infection [2]. This disorder is highly treatable and
warrants prompt recognition. The described prevalence in
Western countries is 39 to 144 per million [3–5]. The study by
Ross et al describes the underlying aetiology of Addison’s disease
in a cohort of South Africans, which is predominated by
autoimmunity [6].
Addison’s disease, like syphilis has been referred to as one of the
great mimickers of medicine. It is therefore not surprising that a
cross-sectional study from Germany found a significant delay in
making the diagnosis, as 20% of the subjects had symptoms for
longer than five years prior to being diagnosed [7]. The vast
majority of cohort studies of Addison’s disease emanate from
Western countries and only isolated reports from Africa describe
the clinical presentation [8,9].
We wished to describe the clinical presentation of Addison’s
disease in South Africa, with the hypothesis that the presentation
may be similar to Western countries, albeit that the signs and
symptoms may be more severe due to the lack of access to health-
care. It is expected that a description of the clinical presentation of
this disorder will serve to remind clinicians of this disorder so that
this diagnosis is not missed.
Methods
Patients
A national database of patients with Addison’s disease was
compiled from primary care, referral centres and private practices.
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Method of Registry Compilation
Since databases in South Africa were not available for Addison’s
disease, a systematic approach was adopted of initially inviting
patients attending quaternary hospitals, followed by patients
attending tertiary hospitals and private care facilities. This was
followed by inviting prospective participants attending both
secondary and primary health-care facilities between the years
2005–2010. A private commercial database (MedPages) of medical
specialists and general practitioners sent in addition, 9 600
personalised e-mails to all specialist physicians, paediatricians and
general practitioners registered with this organisation. As Ad-
dison’s disease is designated as a medical condition that enjoys the
prescribed minimum benefit, it is a statutory requirement that
patients belonging to a medical aid have the total cost of their
treatment reimbursed. [10] The medical insurance companies
were only able to communicate the names of the treating
physicians of Addison’s patients to our research group of those
patients registered, in order to prevent a breach of confidentiality.
These treating physicians were then requested by letter or e-mail
to invite his or her patients to participate in the study.
Ethics and Informed Consent
Approval to conduct the study was obtained from the Research
and Ethics committee of the University of Cape Town, which
endorses the latest declaration of Helsinki. Ethics approval was
also obtained from the respective research and ethics committees
overseeing the various faculties of health sciences including Nelson
Mandela School of Medicine, University of KwaZulu-Natal,
University of the Free State, University of Stellenbosch, University
of Pretoria and the University of Witwatersrand. All participants
signed written informed consent.
Confirmation of Addison’s Disease and Clinical
Presentation
The diagnosis of Addison’s disease was made on the basis of a
suggestive clinical presentation, low basal cortisol concentration
and simultaneously elevated adrenocorticotrophic hormone
(ACTH) concentration, or where indicated, a peak cortisol,
following 250 mg ACTH stimulation of less than 550 nmol/L,
associated with a basal raised plasma ACTH, exceeding
10.1 pmol/L. These criteria have been published previously
[11]. Addison’s disease was confirmed in each case by specialist
internist, paediatrician or endocrinologist. They were also only
considered eligible if they were resident in South Africa. The
clinical symptoms of the patients at diagnosis of Addison’s disease
were elicited by interviewing them at the time of enrolment and
where possible, the clinical details from the notes at the time of
presentation were included in the database.
Statistical Methods
Patient characteristics with non-normal distribution were
described using median and interquartile range. Continuous data
were compared between groups using the Mann-Whitney and chi-
squared tests were used for comparisons of binary and categorical
variables. Binomial confidence intervals (CI) were used as a
measure of the precision of the estimate. All analyses were
conducted were conducted using Stata (TM) version 10.0 (Stata
Corp., College Station, Texas).
Results
There were 161 patients who were referred for enrolment in
the South African Addison’s study. Seven patients with an
original label of Addison’s disease were excluded: two had a
normal ACTH stimulation test, two had secondary hypoadren-
alism, one had a bilateral adrenalectomy for Cushing’s disease,
and two had suppression of the hypothalamic-pituitary-adrenal
(HPA) axis, related to previous steroid use for another
indication. Three patients declined to participate, citing personal
reasons and a further three patients were too late to be enrolled
in this observational study. Thus, a total of 148 patients were
enrolled in the study and we had obtained 92 (62.1%)
transcripts describing the original clinical presentation. The
referral pattern for the patients enrolled in the study is
illustrated in figure 1.
Demographic Data
The demographic data are shown in Table1. The majority of
the patients lived in urban areas (87%), whereas isolated pockets
of patients were identified in the northern part of the Western
province, southern Cape and various districts of Kwazulu-Natal.
Urban Prevalence
While the overall prevalence for this nationwide study was
calculated at 3.1 per million, the urban specific prevalence was
determined. The Western Cape demonstrated urban prevalence
was 13.6 per million, followed by the Eastern Cape 4.7 per
million, Gauteng 2.5 per million, Free State 1.8 per million,
Northern Cape 1.7 per million and Kwazulu-Natal 0.58 per
million.
Clinical Characteristics
The most common presenting sign was hyperpigmentation
(76%), followed by symptoms related to the gastrointestinal
system, and with nausea and vomiting being reported by more
than 40% of the participants (Table 2). Weight loss was
reported in 25%. A significant number reported having suffered
loss of consciousness at presentation (20% 95% CI 14–28%),
had a history of collapse (7%, 95% CI 2.9–11.1%) and suffered
from shock (5%, 95% CI 1.5–8.5%). Any of these three features
could be suggestive of an Addisonian crisis, but the presence of
shock is most convincing for an Addisonian crisis. Backache
occurred in 20%, while dizziness (11%) and salt craving
occurred in 15%. The latter two symptoms are suggestive of
mineralocorticoid deficiency, but dizziness may also be a feature
of glucocorticoid deficiency. Non-specific symptoms such as
malaise and lassitude were noted in 8% and 3% of the cohort
were noted to have hypoglycaemia as their presenting symp-
toms. Thus, the true number of patients who presented with an
Addisonian crisis may be higher than 5%.
Co-morbidity Reported at Enrolment
As seen from Table 3, hypertension, hypercholesterolaemia and
type 2 diabetes mellitus were the most prevalent cardiovascular
conditions. A prior history of pulmonary tuberculosis was the most
common respiratory condition. There were numerous infrequently
encountered co-morbid conditions (#1%), such as inter-alia
steatosis of uncertain aetiology, prosthetic cardiac valve replace-
ment, pulmonary emboli and chronic obstructive pulmonary
disease. Hypothyroidism, type 1 diabetes mellitus, premature
ovarian failure, coeliac disease were the most common associated
autoimmune conditions.
Biochemistry at Diagnosis
There was adequate biochemistry for the diagnosis of Addison’s
disease in 72% of the cases (Table 4). This was defined by the
presence of at least one of suggestive electrolytes (hyponatraemia
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and hyperkalaemia), low morning cortisol and simultaneously
elevated ACTH levels or an inadequate cortisol response to an
ACTH stimulation test. The high proportion of patients (28%)
with inadequate biochemical verification is likely to be due to the
study design in that these data were obtained retrospectively, in
some instances several years prior to being enrolled in the study.
Although some patients had multiple biochemical data available,
diagnostic ACTH stimulation tests were available in 38 (26%),
early morning cortisol and simultaneously elevated ACTH levels
in a further 52 (36%) and suggestive biochemistry in 15 patients
(10%). The respective median basal and stimulated cortisol
concentrations were 58 nmol/L 82 nmol/L, range 5.9 to
476 nmol/L. Concentrations of ACTH greater than 10.1 pmol/
L were considered appropriately elevated for this range of cortisol,
which corroborates the presence of primary hypoadrenalism. The
105 patients with adequate or suggestive biochemistry were
compared to the 43 patients with insufficient biochemical
verification data. The single difference identified was that more
patients with an adequate or suggestive biochemistry presented
with vomiting, compared with the subjects with insufficient
biochemical verification (table 5).
Figure 1. Flow diagram illustrating the pattern of referrals from each of the clinical service tiers for the years 2005–2010. As far as is
known only 3 patients declined to participate, citing personal reasons. N: numbers of patients enrolled. Seven patients were excluded as 2 had a
normal ACTH stimulation test, 2 had secondary hypoadrenalism, 1 had a bilateral adrenalectomy for Cushing’s disease, and 2 had suppression of the
hypothalamic-pituitary adrenal (HPA) axis, related to previous steroid use for another indication.
doi:10.1371/journal.pone.0053526.g001
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Replacement Therapy
Most patients (76%) received a combination of fludrocortisone
and hydrocortisone. Prednisone in combination with hydrocorti-
sone was the next most common combination of steroid
replacement administered (table 6). The median total daily
hydrocortisone dose was 20 mg and the total median dose of
hydrocortisone corrected for body surface area (hydrocortisone/
m2) was 12.4 mg. In this cohort, 33% were receiving three daily
doses, 52% were receiving two daily doses and 15% were receiving
a single daily dose of glucocorticoid replacement therapy. In
addition, 38% of patients reported having had at least one lifetime
Addisonian crisis and 58% of patients did not wear any form of
medical alert identification. The only patient who used dexameth-
asone as replacement therapy, was receiving a significantly greater
glucocorticoid exposure than any of the other patients.
Discussion
There are numerous cohort studies of Addison’s disease in the
literature, but this is the only one conducted in sub-Saharan Africa
Table 1. Demographic data of 148 patients.
Variable
Gender
Males N (%) 57 (39)
Females N (%) 91 (61)
Age at enrolment years (IQR) 46.0 (32.0–61.0)
range (years) 2.8–88.0
Age at initial diagnosis years (IQR) 34.0 (20.0–45.0)
range (years) 0.02–77.0
Ethnicity
Whites N (%) 97 (66)
Mixed Ancestry N (%) 34 (23)
Asian N (%) 5 (3)
Black N (%) 12 (8)
Foreign ancestry1 N (%) 51 (34)
Resident in urban areas N (%) 128 (87)
N: number.
IQR: interquartile range.
1: First or second degree foreign relative from the United States of America or
Europe.
doi:10.1371/journal.pone.0053526.t001
Table 2. Addison’s disease: clinical presentation.
Presenting symptom N Proportion of the cohort (%)
Self-reported increase in skin pigmentation 112 76
Nausea 76 51
Vomiting 63 43
Weight loss 37 25
Abdominal pain 31 21
Loss of consciousness 30 20
Backache 29 20
Salt craving 22 15
Diarrhoea 21 15
Dizziness 16 11
Malaise/lassitude 12 8
History of collapse 10 7
Shock 7 5
Hypoglycaemia 4 3
Anorexia 4 3
Hypoglycaemia 4 3
Anorexia 4 3
N number:
The proportion of 148 Addison’s disease patients who manifested with any of these symptoms at presentation.
doi:10.1371/journal.pone.0053526.t002
Table 3. Co-morbidity reported at enrolment.
System Medical conditionS n/N (%)
Cardiovascular system Hypertension 22/148 (15)
Type 2 diabetes mellitus 9/148 (6)
Hypercholesterolaemia 7/148 (5)
Ischaemic heart disease 4/148 (3)
Cerebrovascular disease 3/148 (2)
Respiratory system Tuberculosis 11/148 (7)
Rheumatological Osteoporosis 7/148 (5)
Antiphospholipid syndrome 4/148 (3)
Other Osteoarthritis 3/148 (2)
type 1 diabetes mellitus 11/148 (7)
n: Number of patients found to have a co-morbid illness.
N: Total number of Addison’s subjects.
S: Excludes medical conditions occurring in less than 1% of the patients, for
example, steatosis, prosthetic cardiac valve replacement, pulmonary emboli
and chronic obstructive airways disease.
doi:10.1371/journal.pone.0053526.t003
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and it can be considered to represent a large cohort as 148 patients
were enrolled [5,12,13]. Although an extensive effort was made to
identify every person with Addison’s disease in South Africa, it is
possible that some patients may not have been captured. The
cohort was generated from referrals of all tiers of hospital services
in South Africa, where no databases for this disease are kept,
except within the domains of the medical insurance companies. In
most cohort studies, the participants were exclusively drawn from
academic centres, with the exception of two reports [7,14]. In this
study and that of Soule, loss of consciousness and confusion were
recorded as presenting symptoms, which suggests that patients
with Addison’s disease may present in a more advanced state of ill-
health, compared to their first world counterparts [11]. For
example, none of the 216 patients in a German cohort appeared to
manifest with an overt Addisonian crisis [7].
Although we attempted to obtain a complete biochemistry
dataset for each of the patients, this is not possible, because in
many instances patients had been diagnosed with Addison’s
disease up to 20 years prior to being enrolled in the study and early
clinical and biochemical records of the initial admission were not
available. Biochemical data compatible with the diagnosis were
available for at least 72% of the patients enrolled. Nevertheless,
there is no reason to doubt the diagnosis of primary hypoadren-
alism, since the diagnosis was made by experienced specialist
physicians, paediatricians, and endocrinologists and we verified
that the clinical picture at presentation was compatible with this
diagnosis. The clinical characteristics were similar in the groups of
patients with adequate biochemistry in the group with an adequate
biochemistry verification data.
Based on the data from Lovas et al and Ten et al [3,4], the
prevalence of Addison’s disease is estimated to vary from 39 to
117 per million, but it has been recorded as high as 144 per
million [5]. Even using conservative estimates, this is considerably
higher than the 3.1 per million found in the current study. It is
likely that this cohort may have not included all cases of Addison’s
disease as the majority of the participants were expected to be
black African, with similar numbers of white mixed ancestry
patients and a small number of Asian patients. The predominantly
white patients in this study may reflect that the evolution of
Addison’s disease is dependent on certain HLA frequencies,
genetic variations or environmental factors, creating favourable
conditions that promote a greater prevalence among whites [15].
As 87% of the cohort was found to be resident in urban areas, we
examined the urban specific prevalence, which varied from
13.6 per million to 0.58 per million, which is still considerably
lower than reported in Western studies. The wide range of urban
specific prevalence may reflect that the Western Cape has
comparatively has a more favourable doctor to patient ratio. See
www.hst.org.za accessed November 2012. It may also reflect that
the researchers originated from the Western Cape and had the
Table 4. Biochemistry at initial diagnosis of Addison’s disease.1
Reference range
NHLS n/N (%) Missing data n/N (%) Median
Inter-quartile
range Range
Basal cortisol(nmol/L)** 171.0–536.0 89/148 (59) 59/148 (40) 58.0 23.8–114 0.0–398
Stimulated cortisol
(nmol/L)**
.550.0 38/148 (26) 110/148 (74) 82.0 49.8–20.8 0–476
Plasma ACTH (pmol/L)** 1.0–10.1 50/148 (34) 98/148 (66) 376 178–973 12.2–1878
Serum Na (mmol/L)** 135.0–147.0 52/148 (35) 96/148 (65) 129.0 125–136 101–145
Frequency of
hyponatraemia
35/52 (62)
Serum K (mmol/L)** 3.5–5.3 49/148 (33) 99/148 (67) 5.2 4.5–5.8 3.8–8.4
Frequency of
hyperkalaemia
17/49(35)
Renin (mU/L)** 7.0–76.0 22/148(15) 126/148 (85) 62.0 24–470 12–5500
Frequency of
hyperreninemia
11/22 (50)
Aldosterone (pmol/L)** 110.0–860.0 23/148 (16) 125/148 (84) 30.9 25–139 0.09–344
Frequency of
hypoaldosteronaemia
18/23 (78)
Serum TSH (mIU/L) 0.35–5.5 50/148 (34) 98/148 (66) 2.43 1.07–7.83 0.01–100
Frequency of
hypothyroidism
13/50 (26)
Serum free T4 (pmol/L) 11.5–22.7 37/148 (25) 111/148 (75) 14.2 10.4–17.0 0.1–26.8
1:different assay methods were used for each of the different analytes, but are included together for comparison.
n: Number of patients identified with available biochemical parameter.
N: Total number of Addison’s patients.
Plasma ACTH plasma adrenocorticotrophic hormone.
Serum Na: Serum sodium.
Serum K: Serum potassium.
Serum TSH: Serum thyroid stimulating hormone.
Serum free T4: Serum free thyroxine.
**Laboratory investigations are not mutually exclusive.
NHLS: National Health Laboratory Services.
Reference ranges as offered by the National Health Laboratory Services of 2011.
Reference ranges likely differed as different assays were used in the diagnosis.
doi:10.1371/journal.pone.0053526.t004
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Table 5. Clinical characteristics of Addison’s patients with adequate or suggestive biochemistry compared to those with
insufficient biochemical verification.
Clinical characteristics Adequate or suggestive biochemistry Insufficient biochemical verification p - value
Number 105 43
Age of enrolment years (IQR) 31.0 (35.0–62.0) 41.0 (21.5–54.5) 0.12
Age at initial diagnosis 34.0 (20.0–46.8) 30.0 (16.3–42.5) 0.26
Gender Female N (%) 67 (64) 24 (58) 0.46
Ethnicity N (%) 0.28
White ancestry 72 (69) 25 (56)
Mixed ancestry 23 (22) 11 (26)
Asian 4 (4.5) 1 (2)
Black 6 (5.5) 6 (14)
Foreign ancestry N (%)1 36 (34) 15 (35) 0.49
Presenting symptoms N (%)
Pigmentation 77 (73) 31 (72) 0.72
Nausea 57 (54) 19 (44) 0.36
Vomiting 51 (49) 12 (28) 0.02
Weight loss 25 (24) 12 (28) 0.60
Abdominal pain 22 (21) 9 (21) 1.0
Backache 23 (22) 6 (14) 0.27
Loss of consciousness 23 (22) 7 (16) 0.60
Diarrhoea 18 (17) 3 (7) 0.18
Salt craving 16 (15) 6 (14) 0.84
Dizziness 10 (10) 6 (14) 0.43
Delay in diagnosis months (IQR) 6.0 (3.0–18.0 5.0 (2.0–13.0 0.28
Comorbidity of enrolment N (%)
Hypercholesterolaemia 5 (5) 2 (5) 0.70
Type 2 diabetes mellitus 7 (7) 2 (5) 0.93
Hypertension 18 (17) 4 (9) 0.80
Ischaemic heart disease 3 (3) 1 (2) 0.71
Cerebrovascular disease 1 (0.7) 2 (2) 0.42
Tuberculosis 7 (7) 4 (9) 0.83
Replacement therapy
total daily hydrocortisone dose mg (IQR) 20.0 (20.0–30.0) 25.0 (20.0–30.0) 0.91
N: number.
1: first or second degree foreign relative from the United States of America or Europe.
doi:10.1371/journal.pone.0053526.t005
Table 6. Glucocorticoid replacement therapy in South African Addison’s disease patients.
Preparation n/N(%) Median daily dose (IQR)
Equivalent hydrocortisone
dose/kg (IQR)
Equivalent hydrocortisone dose/
m2 (IQR) [29]
Hydrocortisone 112/148 (76) 20.0 (20-30.0) 0.33 (0.25-0.44) 12.4 (10.3-16.9)
Cortisone acetate 3/148 (2.0) 25.0 (25.0-32.5) 0.53 (0.50-0.55) 19.7 (18.3-21.0)
Prednisone 10/148 (8) 8.75 (5.0-11.9) 0.42 (0.3-0.68) 16.6 (11.36-26.3)
Dexamethasone 1/148 (0.7) 5 1.31 62
n: Total number of patients identified using a specific form of glucocorticoid replacement therapy.
N: Total number of Addison’s patients enrolled in this analysis.
IQR: Inter-quartile range.
Hydrocortisone dose/m2: Total daily hydrocortisone dose, corrected for body surface area.
Hydrocortisone dose/kg: Total daily hydrocortisone dose corrected for body weight.
Missing data in 22/148 (15%), patients untraceable.
Equivalent doses derived from Meikle AW and Tyler FH. Potency and duration of action of glucocorticoids. Am J of Med 1977;63;200 [29].
doi:10.1371/journal.pone.0053526.t006
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greatest interest in finding cases. The highest prevalence in the
Western Cape may also reflect the minor differences in ethnic
make-up, compared to the remaining provinces. See www.statssa.
gov.za accessed November 2012.
Another possible explanation is that patients with Addison’s
disease may die with the disease unrecognised. Addison’s disease is
regarded as one of the great mimickers of medicine. Although
hyperpigmentation is a significant clinical feature in whites, it may
be more subtle in darkly pigmented races, resulting in the
diagnosis being overlooked [11,16,17]. The disease may also be
unrecognised due to the challenged health-care system, with some
facilities having only 7% of the required number of doctors
[18].Enhancing awareness of Addison’s disease may be achieved
by providing annotations on chemical pathology reports alerting
clinicians to the possibility that primary hypoadrenalism may
coexist with compatible biochemistry. This should be tempered by
the fact that recent interpretive commenting was diverse, incorrect
in some cases and potentially misleading [19]. Awareness of
Addison’s disease should be raised among medical students.
Analogous to the explanation of the low incidence of Addison’s
disease in rural settings is a lower incidence of type 1 diabetes
mellitus in rural Africa, where the ratio of medical practitioners to
population is considerably less than the cities [20]. The
distribution example systemic lupus erythematosis (SLE) has also
been found to vary, even with in an urban district, suggesting that
geographical factors may play a role in modifying an autoimmune
process [21]. Taken together, the few black patients enrolled in
our study may reflect the sub-optimal health delivery in rural areas
and the particular challenge in making this diagnosis in pigmented
races.
In some respects, this cohort is congruent with the findings of
previous studies, for example multiple authors have confirmed the
preponderance of women in the cohorts [12,14] and the age of
diagnosis is similar to many studies of adult Addison’s disease
[13,22,23]. As can be anticipated, the age of onset in paediatric
Addison’s disease population differs substantially, as the median
age of onset was 7.7 years in the study by Simm et al [24]. The
constellation of hyperpigmentation, nausea, vomiting and weight
loss should suggest Addison’s disease as attested to by at least three
other studies [7,11,25].
It is concerning that a significant number (58%) of patients did
not wear any formal medical identification in this study, which is
considerably higher than the 40% of type 1 diabetic children, aged
between six years and 17 years of age, who did not wear medical
alert identification that indicated that they were diabetic and
required insulin [26].
The patients in the study appeared to have significant
comorbidity, but it remains unclear whether this is greater than
that experienced by the general population in South Africa. On
the other hand, recent data from the United Kingdom indicate
that aside from expected coexistent autoimmune disease, 65% of
patients with Addison’s disease had an elevated body mass index
(BMI) of greater than 25 kg/m2, 65% of the total cholesterol of
greater than 5 mmol/L, 17.9% is establish spinal osteoporosis and
53.5% of spinal osteopenia, corroborating the fact that Addison’s
patients are burdened by comorbidity [27].
Mortality has not been assessed in patients with Addison’s
disease in South Africa, but in Sweden, this has been examined by
reviewing death registers. Cardiovascular causes of mortality,
especially ischaemic heart disease were twice as common as the
background population. Malignancy with no specific predilection
for a specific sub-type and infectious diseases were also consider-
ably greater than the background population. In the same study,
diabetes irrespective of the type conferred an almost quadruple
mortality in patients compared to the background population [28].
The current study of South African Addison’s disease has
several weaknesses. As it includes a cross-sectional analysis of the
clinical characteristics of Addison’s disease, the diagnosis in many
instances was made several years previously. These, together with
the lack of uniform protocols for evaluating Addison’s disease and
incomplete clinical notes in a diversity functioning health-care
system, probably contributed to the incomplete available data. It
has been noted that the prevalence of Addison’s disease in South
Africa is considerably lower than in Western countries. Access to
health care in rural regions could have accounted for this low
prevalence. Moreover, the symptoms reported at enrolment were
subject to recall bias as the diagnosis was made 12 years
previously. Another potential weakness is that Addison’s patients
who did not survive an acute Addisonian crisis before being
enrolled in the study could have resulted in the prevalence being
underestimated.
This large cohort from sub-Saharan Africa contained small
proportions of black and Asian participants, which do not reflect
the overall demographics of the country. The overall prevalence of
Addison’s disease is considerably lower than Western countries
and the urban specific prevalence is also reduced, likely due to
under diagnosis. As in the rest of the world, the usual constellation
of symptoms and signs suggest Addison’s disease, but it patients
appear to present in an advanced state of ill-health. Raising
awareness of this highly treatable condition is important and is
potentially a life-saving measure.
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